BLUE vs. ALVR, SGMO, JSPR, AURA, TRML, STRO, CCCC, AVXL, TNYA, and AGEN
Should you be buying bluebird bio stock or one of its competitors? The main competitors of bluebird bio include AlloVir (ALVR), Sangamo Therapeutics (SGMO), Jasper Therapeutics (JSPR), Aura Biosciences (AURA), Tourmaline Bio (TRML), Sutro Biopharma (STRO), C4 Therapeutics (CCCC), Anavex Life Sciences (AVXL), Tenaya Therapeutics (TNYA), and Agenus (AGEN). These companies are all part of the "biological products, except diagnostic" industry.
bluebird bio (NASDAQ:BLUE) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, community ranking, risk and analyst recommendations.
bluebird bio received 1008 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 71.78% of users gave bluebird bio an outperform vote while only 57.45% of users gave AlloVir an outperform vote.
87.4% of bluebird bio shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 2.1% of bluebird bio shares are held by company insiders. Comparatively, 33.9% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
bluebird bio presently has a consensus target price of $5.46, suggesting a potential upside of 504.66%. AlloVir has a consensus target price of $18.50, suggesting a potential upside of 2,350.66%. Given AlloVir's higher possible upside, analysts clearly believe AlloVir is more favorable than bluebird bio.
AlloVir has lower revenue, but higher earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.
AlloVir has a net margin of 0.00% compared to bluebird bio's net margin of -419.64%. bluebird bio's return on equity of -34.32% beat AlloVir's return on equity.
bluebird bio has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.
In the previous week, bluebird bio had 3 more articles in the media than AlloVir. MarketBeat recorded 5 mentions for bluebird bio and 2 mentions for AlloVir. AlloVir's average media sentiment score of 1.44 beat bluebird bio's score of 0.71 indicating that AlloVir is being referred to more favorably in the news media.
Summary
bluebird bio beats AlloVir on 11 of the 17 factors compared between the two stocks.
Get bluebird bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
bluebird bio Competitors List
Related Companies and Tools
